Exact Mass: 327.2521788

Exact Mass Matches: 327.2521788

Found 196 metabolites which its exact mass value is equals to given mass value 327.2521788, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Butorphanol

(1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene-4,10-diol

C21H29NO2 (327.2198174)


Butorphanol is only found in individuals that have used or taken this drug. It is a synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain. [PubChem]The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Butorphanol is a mixed agonist-antagonist that exerts antagonistic or partially antagonistic effects at mu opiate receptor sites, but is thought to exert its agonistic effects principally at the kappa and sigma opiate receptors. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists D019141 - Respiratory System Agents > D000996 - Antitussive Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics

   

MLS002608513

17-Methylandrosta-2,4-dieno[2,3-d]isoxazol-17beta-ol

C21H29NO2 (327.2198174)


   

(9E)-9-nitrooctadecenoic Acid

(9E)-9-nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


(9E)-9-nitrooctadecenoic Acid, also known as (e)-9-Nitrooctadec-9-enoate, is classified as a member of the Long-chain fatty acids. Long-chain fatty acids are fatty acids with an aliphatic tail that contains between 13 and 21 carbon atoms. (9E)-9-nitrooctadecenoic Acid is considered to be practically insoluble (in water) and acidic. (9E)-9-nitrooctadecenoic Acid is a fatty acid lipid molecule

   

(9E)-10-nitrooctadecenoic Acid

(9E)-10-nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


(9E)-10-nitrooctadecenoic Acid, also known as 10-Nitroelaidic acid or (e)-10-Nitrooctadec-9-enoate, is classified as a member of the Long-chain fatty acids. Long-chain fatty acids are fatty acids with an aliphatic tail that contains between 13 and 21 carbon atoms. (9E)-10-nitrooctadecenoic Acid is considered to be practically insoluble (in water) and acidic. (9E)-10-nitrooctadecenoic Acid is a fatty acid lipid molecule

   

Margaroylglycine

2-[(1-Hydroxyheptadecylidene)amino]acetate

C19H37NO3 (327.27732920000005)


Margaroylglycine is an acylglycine with C-17 fatty acid group as the acyl moiety. Acylglycines 1 possess a common amidoacetic acid moiety and are normally minor metabolites of fatty acids. Elevated levels of certain acylglycines appear in the urine and blood of patients with various fatty acid oxidation disorders. They are normally produced through the action of glycine N-acyltransferase which is an enzyme that catalyzes the chemical reaction: acyl-CoA + glycine ↔ CoA + N-acylglycine. Margaroylglycine is an acylglycine with C-17 fatty acid group as the acyl moiety.

   

Norelgestromin

15-Ethyl-14-ethynyl-5-(hydroxyimino)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-ol

C21H29NO2 (327.2198174)


Norelgestromin is only found in individuals that have used or taken this drug. It is a drug used in contraception. Norelgestromin is the active progestin responsible for the progestational activity that occurs in women after application of ORTHO EVRA patch. Norelgestromin inhibits estrone sulfatase, which converts sulfated steroid precursors to estrogen during pregnancy. Norgelgestromin/ethinylestradiol suppresses follicular development, induces changes to the endometrium, which decreases chances of implantation and thickens the cervical mucus, impeding sperm swimming into the uterus. It also has similar agonisting binding affinities as its parent compound, Norgestimate, for progesterone and estrogen receptors. D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents

   

(4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine

3-[(3-hydroxydeca-4,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO5 (327.2045624)


(4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an (4E,6Z)-3-hydroxydeca-4,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine

3-[(3-hydroxydeca-6,8-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO5 (327.2045624)


(6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine is an acylcarnitine. More specifically, it is an (6Z,8E)-3-hydroxydeca-6,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine

3-[(3-hydroxydeca-4,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO5 (327.2045624)


(4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an (4E,7E)-3-hydroxydeca-4,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine

3-[(3-hydroxydeca-5,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO5 (327.2045624)


(5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,7E)-3-hydroxydeca-5,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6E)-Undec-6-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-6-enoyloxy)butanoate

C18H33NO4 (327.2409458)


(6E)-Undec-6-enoylcarnitine is an acylcarnitine. More specifically, it is an (6E)-undec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E)-Undec-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6E)-Undec-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E)-Undec-2-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-2-enoyloxy)butanoate

C18H33NO4 (327.2409458)


(2E)-Undec-2-enoylcarnitine is an acylcarnitine. More specifically, it is an (2E)-undec-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E)-Undec-2-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E)-Undec-2-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5E)-Undec-5-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-5-enoyloxy)butanoate

C18H33NO4 (327.2409458)


(5E)-Undec-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5E)-undec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E)-Undec-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5E)-Undec-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E)-Undec-4-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-4-enoyloxy)butanoate

C18H33NO4 (327.2409458)


(4E)-Undec-4-enoylcarnitine is an acylcarnitine. More specifically, it is an (4E)-undec-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E)-Undec-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E)-Undec-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(7E)-Undec-7-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-7-enoyloxy)butanoate

C18H33NO4 (327.2409458)


(7E)-Undec-7-enoylcarnitine is an acylcarnitine. More specifically, it is an (7E)-undec-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7E)-Undec-7-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (7E)-Undec-7-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undec-3-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-3-enoyloxy)butanoate

C18H33NO4 (327.2409458)


Undec-3-enoylcarnitine is an acylcarnitine. More specifically, it is an undec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undec-3-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undec-3-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undec-9-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-9-enoyloxy)butanoate

C18H33NO4 (327.2409458)


Undec-9-enoylcarnitine is an acylcarnitine. More specifically, it is an undec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undec-9-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undec-9-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undec-8-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-8-enoyloxy)butanoate

C18H33NO4 (327.2409458)


Undec-8-enoylcarnitine is an acylcarnitine. More specifically, it is an undec-8-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undec-8-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undec-8-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

undec-10-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-10-enoyloxy)butanoate

C18H33NO4 (327.2409458)


undec-10-enoylcarnitine is an acylcarnitine. More specifically, it is an undec-10-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. undec-10-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine undec-10-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Palmitoyl Alanine

({2-[(1S,2S,10R,11S,14R,15S)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]-1-hydroxyethenyl}oxy)sulfonic acid

C19H37NO3 (327.27732920000005)


N-palmitoyl alanine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Alanine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Alanine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Alanine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Myristoyl Valine

2-[(1-Hydroxytetradecylidene)amino]-3-methylbutanoate

C19H37NO3 (327.27732920000005)


N-myristoyl valine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Valine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Valine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Valine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

10-Nitrooleate

10-Nitro-9(e)-octadec-9-enoic acid

C18H33NO4 (327.2409458)


   

N-Ethylretinamide

N-ethyl-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide

C22H33NO (327.25620080000004)


   

n-methylsphingosine

N-(1,3-dihydroxyoctadec-4-en-2-yl)formamide

C19H37NO3 (327.27732920000005)


   

Nitro-oleic acid

2-nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


   

18-Nitrooctadec-9-enoic acid

18-Nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


   

(8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-3-nitroso-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol

(8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-3-nitroso-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol

C21H29NO2 (327.2198174)


   
   
   
   

N-(3-Hydroxytetradecanoyl)-DL-homoserine lactone

N-(3-Hydroxytetradecanoyl)-DL-homoserine lactone

C18H33NO4 (327.2409458)


   

3beta-Methylaminopregna-5,17(20)(Z)-dien-16-one

3beta-Methylaminopregna-5,17(20)(Z)-dien-16-one

C22H33NO (327.25620080000004)


   
   
   

1-Methyl-2-dodecyl-4(1H)-quinolone

1-Methyl-2-dodecyl-4(1H)-quinolone

C22H33NO (327.25620080000004)


   

(2E,4E,8E,10E)-octadeca-2,4,8,10-tetraen-12-ynoic acid isobutylamine

(2E,4E,8E,10E)-octadeca-2,4,8,10-tetraen-12-ynoic acid isobutylamine

C22H33NO (327.25620080000004)


   
   
   

18-aminoavarone|3-aminoavarone

18-aminoavarone|3-aminoavarone

C21H29NO2 (327.2198174)


   
   
   

3-acetylviridiflorine

3-acetylviridiflorine

C17H29NO5 (327.2045624)


   
   

19-aminoavarone|4-aminoavarone

19-aminoavarone|4-aminoavarone

C21H29NO2 (327.2198174)


   
   
   
   

3-Oxo-con-4-en|3-oxo-con-4-ene|con-4-en-3-one|Delta4-Conanen-3-on|Latifolinin, Con-4-enin-3-on|latifolinine

3-Oxo-con-4-en|3-oxo-con-4-ene|con-4-en-3-one|Delta4-Conanen-3-on|Latifolinin, Con-4-enin-3-on|latifolinine

C22H33NO (327.25620080000004)


   
   

UR-144 N(4-hydroxypentyl)

UR-144 N(4-hydroxypentyl)

C21H29NO2 (327.2198174)


   

3-hydroxy-C14 homoserine lactone

3-hydroxy-N-(2-oxooxolan-3-yl)tetradecanamide

C18H33NO4 (327.2409458)


CONFIDENCE standard compound; INTERNAL_ID 218

   
   

Levonorgestrel oxime

Levonorgestrel oxime

C21H29NO2 (327.2198174)


   
   
   

9-nitrooctadec-9E-enoic acid

9-nitrooctadec-9E-enoic acid

C18H33NO4 (327.2409458)


   

10-nitro-9E-octadecenoic acid

10-nitro-9E-octadecenoic acid

C18H33NO4 (327.2409458)


   
   

(±)-UR-144 N-(4-hydroxypentyl) metabolite

(±)-UR-144 N-(4-hydroxypentyl) metabolite

C21H29NO2 (327.2198174)


   

9-nitro-9E-octadecenoic acid

9-nitro-9E-octadecenoic acid

C18H33NO4 (327.2409458)


   

NA 19:1;O2

N-(15-methyl-hexadecanoyl) glycine

C19H37NO3 (327.27732920000005)


   

NA 18:2;O3

N-(3-Hydroxy-9Z-hexadecenoyl) glycine

C18H33NO4 (327.2409458)


   

3-[3-(3-aminopropyl)-2,4,8,10-tetraoxaspiro[5.5]undecan-9-yl]propan-1-amine,prop-2-enenitrile

3-[3-(3-aminopropyl)-2,4,8,10-tetraoxaspiro[5.5]undecan-9-yl]propan-1-amine,prop-2-enenitrile

C16H29N3O4 (327.21579540000005)


   

Palmitoyl alanine

N-Hexadecanoyl-L-alanine

C19H37NO3 (327.27732920000005)


   

(2S,3S)-3-(ACETYLOXY)-5-[2-(DIMETHYLAMINO)ETHYL]-2,3-DIHYDRO-2-(4-HYDROXYPHENYL)-1,5-BENZOTHIAZEPIN-4(5H)-ONE

(2S,3S)-3-(ACETYLOXY)-5-[2-(DIMETHYLAMINO)ETHYL]-2,3-DIHYDRO-2-(4-HYDROXYPHENYL)-1,5-BENZOTHIAZEPIN-4(5H)-ONE

C21H29NO2 (327.2198174)


   

Ammonium dodecyl poly oxyethylene sulfate

Ammonium dodecyl poly oxyethylene sulfate

C14H33NO5S (327.20793280000004)


   

1-BOC-4-([2-(MORPHOLIN-4-YL)-ETHYLAMINO]-METHYL)-PIPERIDINE

1-BOC-4-([2-(MORPHOLIN-4-YL)-ETHYLAMINO]-METHYL)-PIPERIDINE

C17H33N3O3 (327.2521788)


   
   

N-Tetradecanoyl-4-hydroxy-L-proline

N-Tetradecanoyl-4-hydroxy-L-proline

C18H33NO4 (327.2409458)


   

(2-hydroxyethyl)ammonium decyl sulphate

(2-hydroxyethyl)ammonium decyl sulphate

C14H33NO5S (327.20793280000004)


   
   

(2R,3S)-1-CARBOXY-4-TRIFLUOROMETHYL-2,3-DIHYDROXYCYCLOHEXA-4,6-DIENE

(2R,3S)-1-CARBOXY-4-TRIFLUOROMETHYL-2,3-DIHYDROXYCYCLOHEXA-4,6-DIENE

C21H29NO2 (327.2198174)


   
   

10-Nitrooleic acid

10-Nitrooleic acid

C18H33NO4 (327.2409458)


D000893 - Anti-Inflammatory Agents

   

N-Ethylretinamide

N-Ethylretinamide

C22H33NO (327.25620080000004)


D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids

   

Ortho Evra

Deacetylnorgestimate

C21H29NO2 (327.2198174)


D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents

   

beta-Aminoarteether

beta-Aminoarteether

C17H29NO5 (327.2045624)


   

17-Methyl-androsta-2,4-dieno(2,3-d)isoxazol-17-ol, (17beta)-

17-Methyl-androsta-2,4-dieno(2,3-d)isoxazol-17-ol, (17beta)-

C21H29NO2 (327.2198174)


   

UR-144 N-(2-hydroxypentyl) metabolite

UR-144 N-(2-hydroxypentyl) metabolite

C21H29NO2 (327.2198174)


   

2-(beta-Diethylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido(3,4-a)indole

2-(beta-Diethylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido(3,4-a)indole

C20H29N3O (327.2310504)


   

Norelgestromin

Deacetylnorgestimate

C21H29NO2 (327.2198174)


C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents

   

N-(Trans-4-{(1s,2s)-2-Amino-3-[(3s)-3-Fluoropyrrolidin-1-Yl]-1-Methyl-3-Oxopropyl}cyclohexyl)-N-Methylacetamide

N-(Trans-4-{(1s,2s)-2-Amino-3-[(3s)-3-Fluoropyrrolidin-1-Yl]-1-Methyl-3-Oxopropyl}cyclohexyl)-N-Methylacetamide

C17H30FN3O2 (327.2321932)


   

(9S)-9-[(8-Ammoniooctyl)amino]-1,2,3,4,9,10-hexahydroacridinium

(9S)-9-[(8-Ammoniooctyl)amino]-1,2,3,4,9,10-hexahydroacridinium

C21H33N3+2 (327.26743380000005)


   

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoate

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoate

C22H31O2- (327.23239259999997)


A polyunsaturated fatty acid anion that is the conjugate base of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(2S)-2-hydroxyphytanate

(2S)-2-hydroxyphytanate

C20H39O3- (327.28990439999995)


Conjugate base of (2S)-2-hydroxyphytanic acid.

   

16-Hydroxy-3,7,11,15-tetramethylhexadecanoate

16-Hydroxy-3,7,11,15-tetramethylhexadecanoate

C20H39O3- (327.28990439999995)


   

Nbeta-methylnorajmaline

Nbeta-methylnorajmaline

C20H27N2O2+ (327.2072422)


   

(2R,3S)-2-octyl-3-hydroxydodecanoate

(2R,3S)-2-octyl-3-hydroxydodecanoate

C20H39O3- (327.28990439999995)


   

(E)-2-nitrooctadec-9-enoic acid

(E)-2-nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


D000893 - Anti-Inflammatory Agents

   

13-Ethyl-17-ethynyl-3-nitroso-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol (non-preferred name)

13-Ethyl-17-ethynyl-3-nitroso-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol (non-preferred name)

C21H29NO2 (327.2198174)


   

N-[(E)-1,3-dihydroxyoctadec-4-en-2-yl]formamide

N-[(E)-1,3-dihydroxyoctadec-4-en-2-yl]formamide

C19H37NO3 (327.27732920000005)


   

Undec-3-enoylcarnitine

Undec-3-enoylcarnitine

C18H33NO4 (327.2409458)


   

Undec-9-enoylcarnitine

Undec-9-enoylcarnitine

C18H33NO4 (327.2409458)


   

Undec-8-enoylcarnitine

Undec-8-enoylcarnitine

C18H33NO4 (327.2409458)


   

(6E)-Undec-6-enoylcarnitine

(6E)-Undec-6-enoylcarnitine

C18H33NO4 (327.2409458)


   

(2E)-Undec-2-enoylcarnitine

(2E)-Undec-2-enoylcarnitine

C18H33NO4 (327.2409458)


   

(5E)-Undec-5-enoylcarnitine

(5E)-Undec-5-enoylcarnitine

C18H33NO4 (327.2409458)


   

(4E)-Undec-4-enoylcarnitine

(4E)-Undec-4-enoylcarnitine

C18H33NO4 (327.2409458)


   

(7E)-Undec-7-enoylcarnitine

(7E)-Undec-7-enoylcarnitine

C18H33NO4 (327.2409458)


   

18-Nitrooctadec-9-enoic acid

18-Nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


   

(4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine

(4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine

C17H29NO5 (327.2045624)


   

(6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine

(6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine

C17H29NO5 (327.2045624)


   

(4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine

(4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine

C17H29NO5 (327.2045624)


   

(5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine

(5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine

C17H29NO5 (327.2045624)


   

(E)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]tetradec-5-enoate

(E)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]tetradec-5-enoate

C18H33NO4 (327.2409458)


   

Ajmalinium

Ajmalinium

C20H27N2O2+ (327.2072422)


Conjugate acid of ajmaline.

   

2-Hydroxyarachidate

2-Hydroxyarachidate

C20H39O3- (327.28990439999995)


A 2-hydroxy fatty acid anion that is the conjugate base of 2-hydroxyarachidic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

3-Hydroxyicosanoate

3-Hydroxyicosanoate

C20H39O3- (327.28990439999995)


A hydroxy fatty acid anion that is the conjugate base of 3-hydroxyicosanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-[(E,1S,2R)-2-hydroxy-1-methylol-heptadec-3-enyl]formamide

N-[(E,1S,2R)-2-hydroxy-1-methylol-heptadec-3-enyl]formamide

C19H37NO3 (327.27732920000005)


   

Glyoxal-lysine dimer

Glyoxal-lysine dimer

C15H27N4O4+ (327.20322020000003)


An imidazolium ion formed via cyclo-dimerisation of L-lysine and glyoxal.

   

3-[[5,5-dimethyl-3-(4-morpholinyl)-1-cyclohex-2-enylidene]amino]-N,N-dimethylaniline

3-[[5,5-dimethyl-3-(4-morpholinyl)-1-cyclohex-2-enylidene]amino]-N,N-dimethylaniline

C20H29N3O (327.2310504)


   

1-(3,5-Dimethylphenyl)-3-(9-prop-2-enyl-9-azabicyclo[3.3.1]nonan-3-yl)urea

1-(3,5-Dimethylphenyl)-3-(9-prop-2-enyl-9-azabicyclo[3.3.1]nonan-3-yl)urea

C20H29N3O (327.2310504)


   

7-methyl-3-(3-methylbutylamino)-1-(1-pyrrolidinyl)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile

7-methyl-3-(3-methylbutylamino)-1-(1-pyrrolidinyl)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile

C19H29N5 (327.2422834)


   

1-[(1-Tert-butyl-5-tetrazolyl)-(4-methylphenyl)methyl]-4-methylpiperidine

1-[(1-Tert-butyl-5-tetrazolyl)-(4-methylphenyl)methyl]-4-methylpiperidine

C19H29N5 (327.2422834)


   
   
   
   

N-cyclobutyl-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2R,5R,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2R,5R,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2S,5S,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2S,5S,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2S,5R,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2S,5R,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2R,5S,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2R,5S,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2S,5R,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2S,5R,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2S,5S,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2S,5S,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2R,5S,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2R,5S,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   
   
   

(12R,13S)-epoxy-(10R)-hydroperoxy-(8E)-octadecenoate

(12R,13S)-epoxy-(10R)-hydroperoxy-(8E)-octadecenoate

C18H31O5- (327.2171376)


   

N-[(E)-1,3-dihydroxyheptadec-4-en-2-yl]acetamide

N-[(E)-1,3-dihydroxyheptadec-4-en-2-yl]acetamide

C19H37NO3 (327.27732920000005)


   

N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]butanamide

N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]butanamide

C19H37NO3 (327.27732920000005)


   

N-[(E)-1,3-dihydroxyoct-4-en-2-yl]undecanamide

N-[(E)-1,3-dihydroxyoct-4-en-2-yl]undecanamide

C19H37NO3 (327.27732920000005)


   

N-[(E)-1,3-dihydroxytridec-4-en-2-yl]hexanamide

N-[(E)-1,3-dihydroxytridec-4-en-2-yl]hexanamide

C19H37NO3 (327.27732920000005)


   

N-[(E)-1,3-dihydroxyhexadec-4-en-2-yl]propanamide

N-[(E)-1,3-dihydroxyhexadec-4-en-2-yl]propanamide

C19H37NO3 (327.27732920000005)


   

N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]pentanamide

N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]pentanamide

C19H37NO3 (327.27732920000005)


   

N-[(E)-1,3-dihydroxyundec-4-en-2-yl]octanamide

N-[(E)-1,3-dihydroxyundec-4-en-2-yl]octanamide

C19H37NO3 (327.27732920000005)


   

N-[(E)-1,3-dihydroxydodec-4-en-2-yl]heptanamide

N-[(E)-1,3-dihydroxydodec-4-en-2-yl]heptanamide

C19H37NO3 (327.27732920000005)


   

N-[(E)-1,3-dihydroxydec-4-en-2-yl]nonanamide

N-[(E)-1,3-dihydroxydec-4-en-2-yl]nonanamide

C19H37NO3 (327.27732920000005)


   

N-[(E)-1,3-dihydroxynon-4-en-2-yl]decanamide

N-[(E)-1,3-dihydroxynon-4-en-2-yl]decanamide

C19H37NO3 (327.27732920000005)


   

butorphanol

butorphanol

C21H29NO2 (327.2198174)


Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists D019141 - Respiratory System Agents > D000996 - Antitussive Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics

   

(9E)-10-nitrooctadecenoic Acid

(9E)-10-nitrooctadecenoic Acid

C18H33NO4 (327.2409458)


A nitro fatty acid that is (9E)-octadec-9-enoic (elaidic) acid substituted by a nitro group at position 10.

   

omega-hydroxyphytanate

omega-hydroxyphytanate

C20H39O3 (327.28990439999995)


An omega-hydroxy fatty acid anion that is the conjugate base of omega-hydroxyphytanic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   

3-hydroxy-N-(2-oxooxolan-3-yl)tetradecanamide

3-hydroxy-N-(2-oxooxolan-3-yl)tetradecanamide

C18H33NO4 (327.2409458)


   

17-Methylandrosta-2,4-dieno[2,3-d]isoxazol-17beta-ol

17-Methylandrosta-2,4-dieno[2,3-d]isoxazol-17beta-ol

C21H29NO2 (327.2198174)


   

Docosahexaenoate

Docosahexaenoate

C22H31O2 (327.23239259999997)


A polyunsaturated fatty acid anion that is the conjugate base of docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

O-undecenoylcarnitine

O-undecenoylcarnitine

C18H33NO4 (327.2409458)


An O-acylcarnitine in which the acyl group is specified as undecenoyl (position of double bond not specified).

   

O-(dimethylnonenoyl)carnitine

O-(dimethylnonenoyl)carnitine

C18H33NO4 (327.2409458)


An O-acylcarnitine in which the acyl group is specified as dimethylnonenoyl (positions of double bond and methyl groups not specified).

   

(9E)-9-nitrooctadecenoic Acid

(9E)-9-nitrooctadecenoic Acid

C18H33NO4 (327.2409458)


A nitro fatty acid that is (9E)-octadec-9-enoic (elaidic) acid substituted by a nitro group at position 9.

   

AcCa(11:1)

Acetyl-CoA carboxylase-alpha(11:1)

C18H33NO4 (327.2409458)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved